Paper40177643
Fc gamma receptor polymorphisms in antibody therapy: implications for bioassay development to enhance product quality.
Twomey JD and 2 others. Antib Ther, 2025. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Fc gamma receptor polymorphisms in antibody therapy: implications for bioassay development to enhance product quality. Papers, record 40177643. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40177643
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Fc gamma receptor polymorphisms in antibody therapy: implications for bioassay development to enhance product quality.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References117
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36776883 | Factors affecting IgG4-mediated complement activation. | Front Immunol | 2023 | https://conductscience.org/library/papers/36776883 | PubMed |
| 2 | 36726033 | The therapeutic age of the neonatal Fc receptor. | Nat Rev Immunol | 2023 | https://conductscience.org/library/papers/36726033 | PubMed |
| 3 | 26497511 | Mouse and human FcR effector functions. | Immunol Rev | 2015 | https://conductscience.org/library/papers/26497511 | PubMed |
| 4 | 37489366 | Detection of Antibody-Dependent Cell-Mediated Cytotoxicity-Supporting Antibodies by NK-92-CD16A Cell Externalization of CD107a: Recognition of Antibody Afucosylation and Assay Optimization. | Antibodies (Basel) | 2023 | https://conductscience.org/library/papers/37489366 | PubMed |
| 5 | 22531445 | Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay. | MAbs | 2012 | https://conductscience.org/library/papers/22531445 | PubMed |
| 6 | 31019955 | NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives. | Ann Transl Med | 2019 | https://conductscience.org/library/papers/31019955 | PubMed |
| 7 | 15153544 | A promoter haplotype of the immunoreceptor tyrosine-based inhibitory motif-bearing FcgammaRIIb alters receptor expression and associates with autoimmunity. II. Differential binding of GATA4 and Yin-Yang1 transcription factors and correlated receptor expression and function. | J Immunol | 2004 | https://conductscience.org/library/papers/15153544 | PubMed |
| 8 | 37764916 | In Vitro Antibody-Dependent Enhancement of SARS-CoV-2 Infection Could Be Abolished by Adding Human IgG. | Pathogens | 2023 | https://conductscience.org/library/papers/37764916 | PubMed |
| 9 | 33440654 | ADCC against MICA/B Is Mediated against Differentiated Oral and Pancreatic and Not Stem-Like/Poorly Differentiated Tumors by the NK Cells; Loss in Cancer Patients due to Down-Modulation of CD16 Receptor. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/33440654 | PubMed |
| 10 | 24487381 | Fcγ receptor IIIA genotype is associated with rituximab response in antimyelin-associated glycoprotein neuropathy. | J Neurol Neurosurg Psychiatry | 2014 | https://conductscience.org/library/papers/24487381 | PubMed |
| 11 | 35814459 | Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies. | Front Oncol | 2022 | https://conductscience.org/library/papers/35814459 | PubMed |
| 12 | 10512162 | Functional CD32 molecules on human NK cells. | Leuk Lymphoma | 1999 | https://conductscience.org/library/papers/10512162 | PubMed |
| 13 | 10742152 | Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. | Nat Med | 2000 | https://conductscience.org/library/papers/10742152 | PubMed |
| 14 | 35332252 | Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires FcγRIIB and virus-antibody complex with bivalent interaction. | Commun Biol | 2022 | https://conductscience.org/library/papers/35332252 | PubMed |
| 15 | 39051331 | NK Cytotoxicity Mediated by NK-92 Cell Lines Expressing Combinations of Two Allelic Variants for FCGR3. | Antibodies (Basel) | 2024 | https://conductscience.org/library/papers/39051331 | PubMed |
| 16 | 17875730 | Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. | Cancer Res | 2007 | https://conductscience.org/library/papers/17875730 | PubMed |
| 17 | 31343409 | FcγRIIB-I232T polymorphic change allosterically suppresses ligand binding. | Elife | 2019 | https://conductscience.org/library/papers/31343409 | PubMed |
| 18 | 28605680 | Surrogate CD16-expressing effector cell lines for determining the bioactivity of therapeutic monoclonal antibodies. | J Pharm Biomed Anal | 2017 | https://conductscience.org/library/papers/28605680 | PubMed |
| 19 | 16115811 | FcgammaRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. | Hum Mol Genet | 2005 | https://conductscience.org/library/papers/16115811 | PubMed |
| 20 | 19164213 | Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19164213 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42614611 | Post-Translational Modification-Driven Metabolic Reprogramming Shapes Melanoma Progression and Immune Microenvironment. | Clin Cosmet Investig Dermatol | 2026 | https://conductscience.org/library/papers/42614611 | PubMed |
| 42086871 | A Cell-Based Reporter Gene Assay for TNF-α Neutralization: Analytical Qualification and Application to Adalimumab and Its Biosimilars. | Pharm Res | 2026 | https://conductscience.org/library/papers/42086871 | PubMed |
| 41992203 | FcγR-driven chimeric receptor T cells in cancer therapy: a novel frontier in antibody-guided immunotherapy. | Cancer Cell Int | 2026 | https://conductscience.org/library/papers/41992203 | PubMed |
| 41577853 | Glycan Profiles of FDA-Approved Therapeutic Antibodies: Insights from Regulatory Submissions. | AAPS J | 2026 | https://conductscience.org/library/papers/41577853 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| FCGR1A | 2209 | PubTator's text mining | https://conductscience.org/library/genes/2209 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40177643
GET https://conductscience.org/api/papers/v1/40177643/references?page=2